Breanna Young, PA
Physician Assistant · Arvada, CONPI 1821695339
Payments from drug & device makers
Across 258 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$953
- Lilly USA, LLC$835
- Mannkind Corporation$493
- Boehringer Ingelheim$489
- Abbott$453
- Insulet Corporation$440
- plus $3K from 25 others
Across 1 payment — averaging $156.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$156
What the payments were for
- Food & beverage$6,63598%
- Education$1042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 28 | $953 |
| Lilly USA, LLC | 37 | $835 |
| Mannkind Corporation | 29 | $493 |
| Boehringer Ingelheim | 19 | $489 |
| Abbott | 21 | $453 |
| Insulet Corporation | 11 | $440 |
| Medtronic | 17 | $396 |
| Novo Nordisk | 12 | $321 |
| Radius Health, Inc. | 14 | $312 |
| Corcept Therapeutics | 3 | $287 |
| Sanofi-aventis U.S. LLC | 8 | $241 |
| Ascensia Diabetes Care US Inc. | 3 | $168 |
| AstraZeneca(2 entities) | 7 | $153 |
| Ascendis Pharma Endocrinology Inc | 2 | $148 |
| Recordati_rare_diseases_inc. | 6 | $142 |
| Dexcom, Inc. | 6 | $127 |
| Xeris Pharmaceuticals, Inc. | 6 | $114 |
| Bayer | 5 | $105 |
| IBSA Pharma Inc. | 5 | $93 |
| Tandem Diabetes Care, Inc. | 3 | $79 |
| Kyowa Kirin, Inc. | 3 | $74 |
| AbbVie | 3 | $68 |
| EUSA Pharma (US) LLC | 2 | $54 |
| Cequr Corporation | 1 | $32 |
| Antares Pharma, Inc. | 1 | $29 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Zealand Pharma US, Inc. | 1 | $26 |
| BETA Bionics, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| GRT US Holding, Inc. | 1 | $19 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,739 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $304,722 |
| CrysvitaBurosumab-Twza | 18 | $286,045 |
| JardianceEmpagliflozin | 154 | $232,601 |
| TrulicityDulaglutide | 111 | $220,165 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 87 | $114,416 |
| MounjaroTirzepatide | 78 | $111,907 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $63,252 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $55,877 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $51,186 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $51,054 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $50,340 |
| Novolog FlexpenInsulin Aspart | 108 | $42,823 |
| RybelsusSemaglutide | 16 | $38,112 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $34,739 |
| FarxigaDapagliflozin Propanediol | 28 | $33,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $321 | $372,783252 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $835 | $340,774216 claims |
| Kyowa Kirin, Inc.Crysvita | $74 | $286,04518 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $489 | $259,005171 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $241 | $50,34024 claims |
| AstraZenecaFarxiga | $153 | $33,83728 claims |
| AbbVieSynthroid | $68 | $13,293121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.
Other physician assistant in Arvada
- Scott PinegarArvada$11K
- Donald MooreEnglewood$246K
- Neekan AeiniGreenwood Village$234K
- Korby HowellCortez$182K
- Heather FinlaysonLittleton$180K
- Kristen LervikDenver$131K
- Marissa Moritz-GuzikLouisville$94K
- Clayton LabaumeDurango$87K
- Emily FrischDenver$79K
- Daniel HumerLone Tree$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.